Clinical trial NCT03416816: A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Official title: A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasms
Keywords: DSP-0337
Lead sponsor: Sumitomo Pharma America, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2018-01-31
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.

Detailed description: The study is comprised of two parts: an initial dose escalation phase utilizing a 3 + 3 design to determine maximum tolerated dose followed by a dose expansion cohort in approximately 30 additional subjects. Study participants will initially receive DSP-0337 orally for 28 days (one cycle of treatment). If clinical benefit is seen, treatment can continue until disease progression.

Eligibility criteria: Inclusion Criteria

1. Histologically or cytologically confirmed diagnosis of advanced cancer in patients with solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
2. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
3. Patients must be at least 18 years of age.
4. Organ function must be adequate as follows:

   * Bone Marrow Reserve: absolute neutrophil count ≥ 1.5 x 10\^9/L; platelet count ≥ 100 x 10\^9/L; hemoglobin ≥ 9.0 g/dL. Must not have required blood transfusion within 1 week of baseline blood count assessment.
   * Hepatic: bilirubin \< 1.5 times the upper limit of normal (ULN); alkaline phosphatase (AP), aspartate transaminase (AST), and alanine transaminase (ALT) \< 3.0 x ULN (AP, AST, and ALT \< 5 x ULN is acceptable if the liver has tumor involvement).
   * Renal: serum creatinine within normal limits; for patients with levels above the institutional normal value, the calculated corrected creatinine clearance must be ≥ 60 mL/min/1.73 m\^2 using the Cockcroft-Gault formula corrected for the body surface area.
5. Toxicities incurred as a result of previous anti cancer therapy (radiation therapy \[RT\], chemotherapy, or surgery) must be resolved to ≤ Grade 1 except for alopecia and anorexia.
6. Patients must provide written informed consent.
7. Female patients are eligible for the study if they meet the following criteria:

   * Are not pregnant or nursing;
   * Of non-childbearing potential defined as women who have had a hysterectomy, bilateral oophorectomy, medically documented ovarian failure, or are documented postmenopausal (follicle stimulating hormone \> 40 mIU/mL); OR,

   Of childbearing potential defined as including women \< 55 years of age, even those who have experienced 2 years of amenorrhea; all women should also meet both of the following criteria:
   * A negative serum or urine pregnancy test during Screening,
   * Sexually abstinent or correct and consistent use of one of the following methods of birth control in addition to a male partner using a condom from Screening to 3 months after the last dose of study drug:
   * hormone-containing contraceptive intrauterine device with a failure rate of \< 1% per year,
   * cervical cap or diaphragm with a spermicidal agent,
   * tubal sterilization, or
   * vasectomy in male partner. Male patients must agree to sexual abstinence or to consistently and correctly use a condom in combination with one of the above methods of birth control from Screening to 3 months after the last dose of study drug.
8. Life expectancy must be ≥ 3 months.

Exclusion Criteria

1. Has received systemic anti-cancer therapy within the 3 weeks prior to starting the trial.
2. Has received radiotherapy within the 28 days prior to first dose or within 12 weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control.
3. Has received major surgery within the 4 weeks prior to starting the trial.
4. Has significant inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
5. Clinically active known brain metastasis unless the brain metastases have been previously treated and are considered stable. Stable brain metastases are defined as no change on computed tomography (CT) scan or magnetic resonance imaging (MRI) for a minimum of 2 months and no change in steroid dose for a minimum of 4 weeks prior to starting the trial.
6. Is pregnant or lactating.
7. Had prior malignancy other than carcinoma in situ of the cervix or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 3 years previously with no subsequent evidence of recurrence. If the patient has a medical history of a previous tumor that is not included in this criteria and that the Investigator feels is irrelevant for the objectives of the study, it should be evaluated with the Sponsor or Medical Monitor.
8. Has a corrected QT interval (QTc) \> 470 ms or has an electrocardiogram (ECG) with a new abnormal finding that is clinically significant.
9. Has a known clinically significant GI disorder(s) including, but not limited to, inflammatory bowel disease or a history of extensive gastric resection and/or small intestinal resection.
10. Has inability to take oral medications and/or has clinical or radiological diagnosis of bowel obstruction.
11. Had prior treatment with napabucasin (BBI-608).
12. Is not able to avoid the concomitant use of proton pump inhibitors (PPIs) or histamine H2-receptors antagonists, which have long-lasting pH-elevating effects, during DSP-0337 dosing, or avoid the use of antacids until at least 2 hours after dosing.
13. Has a known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or untreated hepatitis C; patients who have completed a course of antiviral treatment for hepatitis C are eligible.
14. Has inability to comply with the protocol or study procedures.

Primary outcomes:
measure: Maximum tolerated dose by assessing dose-limiting toxicities (DLTs)
timeFrame: 4 weeks
measure: Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)
timeFrame: 4 weeks
Secondary outcomes:
measure: Number of Patients with Adverse Events
timeFrame: 12 months
measure: Pharmacokinetics by assessing drug concentration in blood
timeFrame: 4 weeks
measure: Urine excretion of napabucasin after DSP-0337 administration
timeFrame: 24 hours
measure: Objective response rate (ORR)
timeFrame: 6 months
measure: Time to progression (TTP)
timeFrame: 6 months
measure: Progression free survival (PFS)
timeFrame: 12 months
Other outcomes:
measure: Exploratory pharmacodynamic evaluation, including phosphorylated STAT3 (pSTAT3) expression level in patient-derived tumor tissue, as potential biomarkers
timeFrame: 12 months
Locations:
city: Indianapolis
country: United States
facility: Indiana University Health Melvin and Bren Simon Cancer Center
state: Indiana
city: Detroit
country: United States
facility: Karmos Cancer Center
state: Michigan
city: San Antonio
country: United States
facility: UT Heatlh San Antonio
state: Texas
city: West Jordan
country: United States
facility: Utah Cancer Specialist
state: Utah
Study officials:
References: